Suhasini Joshi

Bristol-Myers Squibb (United States) — United States

Medicine · Health Sciences

2h-index11citations19works0.42yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(14), Neuroblastoma Research and Treatments(4), Peptidase Inhibition and Analysis(4), Lung Cancer Research Studies(3), Immune cells in cancer(2)

Publications19 total

Data from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Table S2 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Figure S3 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Table S3 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Figure S6 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Table S4 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Figure S7 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Table S5 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Table S1 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Figure S2 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Figure S4 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Figure S1 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Figure S5 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
Cancer Immunology Research·2025· 6 citedOpen Access
A Novel Combination of Zinc Oxide with Two Essential Oils Exerts Antimicrobial Effect against Endodontic Pathogens In Vitro
International Journal of Clinical Pediatric Dentistry·2024Open Access
Biocompatibility of Ajwain Oil Combined with Eugenol and Zinc Oxide as a Deciduous Root Canal Obturating Material: An In Vivo Study
International Journal of Clinical Pediatric Dentistry·2023· 5 citedOpen Access
Galactoside-binding lectin from mistletoe
British Homeopathic journal·1993
Book Reviews
Oncology·1987Open Access
Modulation of in vivo malignancy and in vitro natural killer susceptibility of raw 117 lymphosarcoma cells by butanol
Proceedings of the American Association for Cancer Research Annual Meeting·1986

Frequent Co-authors

Michael Wichroski(14), Si-Qi Liu(14), Lauren M. Zasadil(14), Joseph L. Benci(14), Patrick C. Gedeon(14), Kendall J. Condon(14), Shana Posy(14), Patrick Carlson(14), Alison Maier(14), Jiao Shen(14), Rakeeb Kureshi(14), Yuka Amako(14), Tai Wang(14), Ryan L. Powles(14), Yanyun Li(14), Tho Lai(14), Igor Katsyv(14), Hongchen Qiu(14), Huilin Qi(14), Jessica Wong(14)